Molecular Biology Reports

, Volume 37, Issue 3, pp 1467–1475

Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia

Authors

  • Xiangqian Hou
    • Department of Vascular Surgery, Shandong Provincial HospitalShandong University
  • Xuejun Wu
    • Department of Vascular Surgery, Shandong Provincial HospitalShandong University
  • Junxi Ma
    • Department of Vascular Surgery, Shandong Provincial HospitalShandong University
  • Xinhui Lv
    • Department of Vascular Surgery, Shandong Provincial HospitalShandong University
    • Department of Vascular Surgery, Shandong Provincial HospitalShandong University
Article

DOI: 10.1007/s11033-009-9541-3

Cite this article as:
Hou, X., Wu, X., Ma, J. et al. Mol Biol Rep (2010) 37: 1467. doi:10.1007/s11033-009-9541-3

Abstract

Transplantation of adult marrow stromal cells (MSCs) has been developed as a new method of treating severe ischemia diseases by therapeutic angiogenesis. Erythropoietin (EPO) is capable of inducing angiogenesis and inhibiting MSCs apoptosis. The effect of EPO on the therapeutic potency of MSCs transplantation in a rat model of limb ischemia was investigated in the current study. The results indicate that the combined treatment with MSC transplantation and EPO infusion is superior to MSC transplantation alone in the treatment of limb ischemia. MSCs transplantation and EPO infusion could enhance the angiogenic effect of each other to achieve a better therapeutic effect. This combination therapy may become a more effective approach for ischemia diseases of the limbs.

Keywords

ErythropoietinMarrow stromal cellsLimb ischemia

Copyright information

© Springer Science+Business Media B.V. 2009